Sunday, July 5, 2026
Knowledge FilesSearch
Via News
Via News Knowledge File

AbbVie Inc.

organization80% conf.·synced Jul 5, 2026

Biopharmaceutical company based in North Chicago, Illinois, developing oncology and hematology therapeutics

43
sourced metrics
519
relationships
20
stated objectives
8
Via News reports

Every fact below is drawn from Via News's knowledge graph and linked to the source document it came from. Nothing here is unsourced. How we source →

Key metrics · each point sourced

Stock Price
3.5percent_gain_post_earnings
Jun 1, 2026source
Pipeline Total Programs
90programs
May 25, 2026source
Consecutive Dividend Increases
53years
May 25, 2026source
Mid Late Stage Clinical Trials
60programs
May 25, 2026source
Portfolio Weight In Xlv
7.09percent
May 18, 2026source
Portfolio Weight In Fhlc
6.06percent
May 18, 2026source
Milestone Payment Owed
100USD
May 15, 2026source
Parameter Count
1.73USD_per_share_quarterly_dividend
May 1, 2026source
Eps
2.65USD
Apr 30, 2026source
Forward Pe Ratio
14.3ratio
Apr 19, 2026source
Dividend Increase Streak
53years
Apr 19, 2026source
Valuation Score
2out_of_6
Apr 1, 2026source
Intrinsic Value Per Share
405.03USD
Apr 1, 2026source
Free Cash Flow
17.97USD
Apr 1, 2026source
Donation Per Strikeout
20USD
Mar 24, 2026source
Max Annual Donation
1USD
Mar 24, 2026source
Per Strikeout Donation
20USD
Mar 24, 2026source
Annual Donation Cap
1USD
Mar 24, 2026source

Stated objectives

Develop and commercialize 35+ investigational medicines in multiple clinical trials across hematologic cancers

source
target: 35 stated

Pursue additional international regulatory approvals for the R/R FL indication

source
stated

Evaluate epcoritamab as monotherapy and in combination across lines of therapy in a range of hematologic malignancies through four ongoing Phase 3 trials

source
stated

Achieve adjusted diluted EPS for 2025

source
target: 12.12 to 12.32 USD by 2025-12-31 00:00:00stated

Achieve high single-digit compound annual revenue growth rate for ex-Humira platform

source
target: high single-digit percent by 2029-12-31 00:00:00stated

Achieve combined sales of immunology duo

source
target: 27 billion USD by 2027-12-31 00:00:00stated

Raised full-year earnings guidance

source
target: $10.61-$10.65 EPS by 2025-12-31 00:00:00stated

High single-digit CAGR through 2029

source
target: high single-digit percent CAGR by 2029-01-01 00:00:00stated

Drive long-term growth through early-stage pipeline development

source
stated

Return to robust revenue growth following Humira LOE

source
by 2025-01-01 00:00:00stated

Relationship graph · 519 connections

Developed by
244
Competes with
48
Covered by
41
headquartered in
30
Employs
27
regulates
17
acquired by
12
Invested in
10

Via News coverage

Six FDA Oncology Decisions Due in 2026 — ADCs, Cell Therapies, and Checkpoint Inhibitors Face Global Catalyst Calendar
June 19, 2026
Jade Biosciences Targets 2027 Phase 1 Trial as Global Autoimmune Drug Race Intensifies
February 18, 2026
SM Energy Company And 5 Other Stocks Have High Sales Growth And An Above 3% Return on Equity
October 8, 2024
John Hancock, Peoples Bancorp, Another 6 Companies Have A High Estimated Dividend Yield
October 1, 2024
Blackrock MuniHoldings New Jersey Quality Fund, American Software, Another 3 Companies Have A High Estimated Dividend Yield
September 25, 2024
AbbVie And 5 Other Stocks Have Very High Payout Ratio
September 22, 2024
Lincoln National Corporation And 4 Other Stocks Have High Sales Growth And An Above 3% Return on Equity
September 15, 2024
AbbVie And 4 Other Stocks Have Very High Payout Ratio
September 11, 2024
This Knowledge File is assembled from Via News's source-traceable knowledge graph. Metrics, objectives and relationships are extracted from primary and credible secondary documents and refreshed on a schedule. Read our methodology →